Welcome to our dedicated page for Viatris news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris stock.
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company that bridges the gap between generics and branded medicines, aiming to address healthcare needs more comprehensively worldwide. Formed in November 2020 by the merger of Upjohn, a subsidiary of Pfizer, and Mylan, Viatris leverages its vast portfolio to provide high-quality medications to approximately 1 billion patients annually across more than 165 countries. The company’s operations span 10 major therapeutic areas, with a strategic focus on dermatology, ophthalmology, and gastroenterology.
Viatris boasts an extensive product lineup, including around 1,400 generic pharmaceuticals and several branded medications like Lipitor, Norvasc, Lyrica, and Viagra. Generics and biosimilars form about 40% of its sales, while legacy products contribute to the remaining 60%. The company is also a key supplier of antiretroviral therapies, which nearly 50% of HIV/AIDS patients in developing countries rely on.
In 2023, Viatris continued to make strides with significant developments. It announced positive results from the YUPELRI® Phase III clinical trial in China for COPD treatment, paving the way for regulatory approval anticipated in mid-2024. The company also entered a substantial R&D collaboration with Idorsia Ltd, acquiring global rights to two promising Phase 3 assets: selatogrel, for acute myocardial infarction, and cenerimod, for systemic lupus erythematosus. Additionally, Viatris launched RYZUMVI™, an FDA-approved eye drop for reversing pharmacologically-induced dilation, further expanding its ophthalmology portfolio.
Financially, Viatris demonstrated robust performance with consistent operational revenue growth. The company reported a strong 2023, meeting its financial guidance, and executed strategic initiatives like the divestiture of its Women's Healthcare Business and API business in India. Viatris also maintained a solid cash flow, allowing it to return capital to shareholders through dividends and share repurchases, reinforcing its commitment to shareholder value.
Headquartered in the U.S., with major centers in Pittsburgh, Shanghai, and Hyderabad, Viatris employs around 30,000 people dedicated to advancing global health. For more information, visit viatris.com.
Viatris Inc. (NASDAQ: VTRS) has announced the pricing terms for its previously announced cash tender offers for two series of senior notes. The offers include:
- Any and all of the outstanding 1.650% Senior Notes due 2025 issued by Viatris
- Any and all of the outstanding 2.125% Senior Notes due 2025 issued by Mylan Inc.
The tender offers are set to expire at 5:00 p.m., New York City time, on September 10, 2024. The Total Consideration for each $1,000 principal amount of Viatris Notes is $977.66, while for each €1,000 principal amount of Mylan Notes, it's €994.12. These prices include accrued and unpaid interest up to, but not including, the expected settlement date of September 16, 2024.
Viatris, a global pharmaceutical company, released its 2023 Sustainability Report highlighting efforts to break down systemic barriers to medicine access through policy engagement. As a member of ~160 trade associations, Viatris leverages its global experience and expertise to support policymakers in developing policies that advance access to quality medicines.
Key initiatives in 2023 included:
- Advancing regulatory harmonization through participation in International Council on Harmonization (ICH) working groups
- Supporting the UK's Windsor Framework to protect post-Brexit medicine access
- Partnering with the Center for Research on Complex Generics in the U.S.
- Assessing localization policies' impact on medicine access
- Engaging in the European Pharmaceutical Legislation revision
- Supporting studies on healthcare investment and innovative financing for Universal Health Coverage
Viatris' global policy priorities focus on advancing access to quality medicines, strengthening resilient global supply, and building future access across diverse therapeutic areas and geographies.
Viatris' 2023 Sustainability Report highlights significant progress in combatting infectious diseases like HIV, TB, malaria, and hepatitis. Viatris has expanded access to high-quality HIV/AIDS treatment, including self-testing diagnostics, pediatric therapies, and innovative formulations. In 2023, Viatris developed a dual oral pill for HIV and birth control with the Bill and Melinda Gates Foundation, targeting WHO approval by end-2024. The company also partnered with DNDi for slow-release flucytosine to treat cryptococcal meningitis.
Viatris supports local ARV manufacturing and engages in licensing agreements with organizations like Gilead and Viiv Healthcare. Over 32% of people on HIV treatment globally use Viatris products. In India, Viatris launched a single pill HIV treatment reaching 4,000 patients in six months. The company offers more than 700 infectious disease product registrations across LMICs.
In the fight against TB, Viatris introduced pretomanid for multidrug-resistant strains, approved in 57 countries. Efforts also extend to hepatitis B and C, with notable initiatives in the Philippines, Myanmar, and Bulgaria. Viatris' partnerships and innovative solutions aim to meet its goal of providing ARV therapy to 30 million patients by 2025.
Viatris Inc. (NASDAQ: VTRS) and its subsidiaries have launched cash tender offers for certain outstanding notes. The offers include:
- Any and all of the 1.650% Senior Notes due 2025 issued by Viatris
- Any and all of the 2.125% Senior Notes due 2025 issued by Mylan
- Up to $450 million aggregate principal amount of the 3.950% Senior Notes due 2026 issued by Utah Acquisition Sub Inc.
The Any and All Tender Offers expire on September 10, 2024, while the Maximum Tender Offer expires on October 2, 2024. Early tender payments are available for the Maximum Tender Offer Notes. The Total Consideration for each offer will be determined based on fixed spreads plus applicable yields. The offers are subject to various conditions and may be amended, extended, or terminated at the Offerors' discretion.
Viatris Inc. (NASDAQ: VTRS) presented results from a Phase 2 study of cenerimod for treating moderate to severe systemic lupus erythematosus (SLE) in Japanese patients at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress. The study, involving 17 patients, evaluated 2 mg and 4 mg doses of cenerimod, a selective S1P1 receptor modulator.
Key findings include:
- Both doses were considered safe and well-tolerated
- Expected decrease in lymphocyte counts, reversible upon treatment discontinuation
- Clinically meaningful improvement in disease activity, measured by mSLEDAI-2K
- Results consistent with the global Phase 2 CARE study
The presentation highlighted cenerimod's potential as a treatment for SLE, showcasing Viatris' commitment to addressing the needs of the SLE community.
Viatris reported Q2 2024 revenues of $3.8 billion, with a 2% operational growth on a divestiture-adjusted basis. New product revenues reached $210 million, driven by Breyna™ and lisdexamfetamine. Despite strong growth, the company reported a GAAP net loss of $326 million and a GAAP EPS loss of $0.27. However, adjusted EBITDA grew by 2% to $1.2 billion and adjusted EPS increased by 3% to $0.69 per share.
Viatris raised its full-year new product revenues guidance to $500-$600 million and expects a 2% operational growth. The company completed its divestitures and focuses on its diversified base business, financial strength, and innovative portfolio for future growth.
GAAP net cash from operations was $379 million, and free cash flow, excluding divestiture costs, was $426 million. Viatris also reduced its debt by $800 million.
Viatris (NASDAQ: VTRS) has announced its second quarter 2024 dividend. The company's Board of Directors declared a quarterly dividend of $0.12 per share on August 5, 2024. This dividend applies to all issued and outstanding shares of Viatris' common stock. Shareholders who are on record as of the close of business on August 23, 2024, will receive the dividend payment on September 13, 2024. This announcement demonstrates Viatris' commitment to providing regular returns to its shareholders.
Viatris' 2023 Sustainability Report focuses on initiatives to empower healthcare workers globally, addressing the critical shortfall projected by WHO of 10 million healthcare workers by 2030. The report highlights the NCD Academy, which offers free, web-based educational tools covering major non-communicable diseases (NCDs) and expanded in 2023 with courses on social determinants of health and chronic respiratory diseases.
In 2023, nearly 5,000 new users joined NCD Academy, impacting an estimated 12.6 million patients annually. Viatris also launched Viatris Connect Medical in several countries to keep healthcare professionals updated on the latest medical advances. Additionally, the company supported multiple educational programs worldwide, promoting equitable access to care.
Viatris aims to impact 100 million patients by 2025 through HCP education. The report underscores the importance of partnerships and digital solutions in overcoming barriers to equitable healthcare access.
Viatris, a global pharmaceutical company, emphasizes the importance of a flexible and diverse supply chain in its 2023 Sustainability Report. The company maintains a 90% global customer service level despite market volatility and supply chain disruptions. Viatris has Supply Chain colleagues in over 55 countries, monitoring demand and supply daily with a 24-month outlook.
The company has invested in facilities worldwide, including in lower- and middle-income countries (LMICs), to strengthen its global network and support local economic development. Notable projects include technology transfer in Vietnam and a WHO-accredited packaging facility in Zambia.
Viatris is progressing towards its goal of providing ARV therapy to 30 million HIV/AIDS patients by 2025. In 2023, they treated approximately 8.6 million patients, including 670,000 children. Since 2022, they've provided treatments for nearly 17 million adults and children living with HIV/AIDS.
Viatris, a global healthcare company, released its 2023 Sustainability Report, highlighting its strategy for sustainable access to medicine. The company's hybrid approach combines generics and brands to address global healthcare needs. Viatris' business model focuses on building and sustaining access to medicine at scale, serving patients and health systems worldwide.
Key points from the report include:
- In 2023, Viatris sold over 80 billion doses of medicine across 165+ countries
- The company offers treatments in 10+ major therapeutic areas
- Viatris is expanding into complex generics and novel products
- The company launched Breyna™, the first FDA-approved generic version of Symbicort®
- Viatris acquired development programs for Selatogrel and Cenerimod in 2024
The report emphasizes Viatris' commitment to access, partnerships, and sustainable operations to meet evolving healthcare needs globally.
FAQ
What is the current stock price of Viatris (VTRS)?
What is the market cap of Viatris (VTRS)?
What is Viatris Inc.?
What products does Viatris offer?
What are Viatris' key therapeutic areas?
What recent collaborations has Viatris announced?
How did Viatris perform financially in 2023?
Where is Viatris headquartered?
What is YUPELRI®?
What is the significance of RYZUMVI™?
What is the mission of Viatris?
How many people does Viatris employ?
